Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).

[1]  R. Stahel,et al.  A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial , 2019, Annals of Oncology.

[2]  S. Lantuejoul,et al.  Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. , 2019, The Lancet. Oncology.

[3]  N. Pavlakis,et al.  Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  I. Ray-Coquard,et al.  Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  S. Barni,et al.  A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma. , 2018, Respiratory medicine.

[6]  S. Novello,et al.  NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. , 2018, The Lancet. Oncology.

[7]  K. Nackaerts,et al.  Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. , 2017, The Lancet. Oncology.

[8]  P. Allavena,et al.  Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models , 2017, British Journal of Cancer.

[9]  R. Stahel,et al.  Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[10]  G. Ceresoli,et al.  Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma. , 2015, Cancer treatment reviews.

[11]  Bingshu E. Chen,et al.  Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome. , 2015, European journal of cancer.

[12]  J. V. van Meerbeeck,et al.  Second line therapy in malignant pleural mesothelioma: A systematic review. , 2015, Lung cancer.

[13]  J. Lafitte,et al.  Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. , 2015, The Lancet. Oncology.

[14]  G. Ceresoli,et al.  Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. , 2014, Lung cancer.

[15]  I. Ray-Coquard,et al.  Lurbinectedin (PM01183), an active compound in platinum-resistant/refractory ovarian cancer (PRROC) patients: Results of a two-stage, controlled phase II study. , 2014 .

[16]  G. Ceresoli,et al.  Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. , 2012, Lung cancer.

[17]  R. Stahel,et al.  Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  A. Tod,et al.  Living with mesothelioma. A literature review. , 2009, European journal of cancer care.

[19]  R. Ramlau,et al.  Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Cindy B. Yeoh,et al.  Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  A. Musk,et al.  Malignant mesothelioma , 2005, The Lancet.

[22]  M. Byrne,et al.  Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  J. V. van Meerbeeck,et al.  The role of gemcitabine in the treatment of malignant mesothelioma. , 2002, Seminars in oncology.

[24]  J. Herndon,et al.  A design alternative for two-stage, phase II, multicenter cancer clinical trials. , 1998, Controlled clinical trials.

[25]  P. V. Van Schil,et al.  Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.